Extrait

To test the hypothesis that oral administration of 32 mg per day of ruboxistaurin will reduce, relative to placebo, the occurrence of SMVL (defined as a 15 letter or more decrease from baseline in best-corrected ETDRS visual acuity in a DR study eye that is sustained for the patient’s last 6 months of study participation).

Critère d'inclusion

• Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the macula and is a microvascular complication of diabetes. In this study patients will have macular edema that meets the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant macular edema (CSME), (but patients with imminently vision threatening macular edema are excluded)

Liens

• euctr
• ictrp
• euctr
• euctr
• ictrp
• ictrp
• euctr
• euctr
• ictrp
• ictrp